Earticle

초록

영어

Background & objective: The Korean government has expanded its benefit coverage to enhance patients' access to orphan drugs and cancer medicines. However, the number of new drugs whose indications were not applied to reimbursement in health insurance was increased. This study aimed to understand the perspectives of experts and various stakeholders on the introduction of a new funding program for cancer treatment and orphan drugs. Methods: We conducted email surveys comprising 19 questions, from September 9 to 26, 2016. We distributed questionnaires to members of the Pharmaceutical Benefit Appraisal Committee and Cancer Assessment Committee. We also conducted a qualitative study through group interviews with stakeholders, including pharmaceutical companies and some patient groups for diseases. Results: A total of 35 survey respondents recommended the introduction of a funding program for orphan drugs, whereas 66% recommended the launch of funding for anticancer drugs. In addition, most pharmaceutical companies and patient groups recommended the introduction of new funding programs targeting patients with cancer and rare diseases. However, some participants asserted that it would be more appropriate to modify the existing reimbursement scheme than launch new funding. Conclusion: This study concluded that introducing new funding needs a social consensus to relieve financial hardships at the patient level.

목차

ABSTRACT
연구 방법
약제급여 의사결정 기구 전문가 위원 대상 설문조사
이해관계자(제약업계, 환자단체) 및 정책실무자 의견 수렴
연구 결과
약제 급여 의사결정 기구 전문가 의견조사 결과
이해관계자(제약업계, 환자단체) 및 실무담당자 의견수렴 결과
고찰 및 결론
이해상충
참고문헌

키워드

저자

• 김수진 [ Sujin Kim | 건강보험심사평가원 심사평가연구실 ]
• 정승연 [ Seungyeon Jung | 의약품정책연구소 연구팀 ]
• 김동숙 [ Dong-Sook Kim | 건강보험심사평가원 심사평가연구실 ] Corresponding Author

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국임상약학회지 [Korean Journal of Clinical Pharmacy]

• 간기

  계간

• pISSN

  1226-6051

• 수록기간

  1991~2026

• 등재여부

  KCI 등재

• 십진분류

  KDC 518 DDC 615